摘要
目的:探讨雄激素受体(androgen receptor,AR)在人表皮生长因子-2(human epidermal growth factor receptor-2,Her-2)过表达型乳腺癌和三阴性乳腺癌(triple-negative breast cancer,TNBC)中的表达情况,及其与临床病理参数的关系。方法:收集本院两种乳腺癌术后病理标本各40例,用免疫组化法检测AR表达情况,统计分析其在两种乳腺癌中的表达情况,且与临床病理的关系。结果:(1)Her-2过表达型乳腺癌和TNBC中AR的阳性率分别为72.5%和37.5%,差异有统计学意义(P<0.01)。(2)Her-2过表达型乳腺癌中,AR表达与淋巴结转移、Ki-67表达有关(P<0.05);TNBC中AR表达与绝经状态、淋巴结转移、Ki-67表达有关(P<0.05)。结论:(1)AR在Her-2过表达型乳腺癌和TNBC中均阳性表达,有望成为新的内分泌治疗靶点。(2)AR拮抗剂在Her-2过表达乳腺癌中的治疗效果可能优于TNBC。
Objective:To explore the expression of androgen receptor(AR)in human epidermal growth factor receptor-2(Her-2)enrich breast cancer and triple-negative breast cancer(TNBC);and its relationship with clinicopathologic parameters.Methods:80 cases of postoperative pathological specimens of two breast cancer patients were collected in our hospital.The expression of AR was detected by immunohistochemistry,and its relationship with clinicopathologic parameters was analyzed.Results:①The positive rates of AR in human epidermal growth factor receptor-2 enrich breast cancer and triple-negative breast cancer were 72.5%and 37.5%(P<0.01).②For human epidermal growth factor receptor-2 enrich breast cancer,there were significant difference in the positive rate of AR in node or not and expression of Ki-67(P<0.05).The expression of AR in TNBC is related to menopausal status,lymph node metastasis and Ki-67 expression(P<0.05).Conclusion:①AR in both breast cancer were positive expression,which may become a new endocrine therapy target.②The effect of androgen receptor antagonists in human epidermal growth factor receptor-2 enrich breast cancer may be superior to that of TNBC.
作者
刘坤
李义强
张洋
胡少军
王博
LIU Kun;LI Yi-qiang;ZHANG Yang;HU Shao-jun;WANG Bo(Department of Oncology,the First Affiliated Hospital of Jiamusi University,Jiamusi 154003,China)
出处
《黑龙江医药科学》
2018年第3期86-88,共3页
Heilongjiang Medicine and Pharmacy
关键词
乳腺癌
Her-2过表达型乳腺癌
三阴性乳腺癌
雄激素受体
breast cancer
human epidermal growth factor receptor-2 enrich breast cancer
triple-negative breast cancer
androgen receptor